[骨质疏松症:高风险患者的治疗]
1LMU Klinikum, Osteologisches Schwerpunktzentrum der LMU - Bayerisches Osteoporosezentrum, Medizinische Klinik und Poliklinik IV, Ziemssenstr. 5, 80336, München, Deutschland. ralf.schmidmaier@med.uni-muenchen.de.
对于骨质疏松症,骨类合成药对高风险患者来说优于抗吸收药. 这些强效的骨质疏松症治疗应该是治疗的第一线,其次是抗吸收药.
科学领域:
- 内分泌学 在内分泌学.
- 整形外科 整形外科 整形外科
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨质疏松症的治疗包括抗吸收药物 (例如,拉洛西芬,双酸盐,德诺苏马布) 和骨代谢剂 (特里巴拉提德,罗莫索祖马布).
- 随机比较研究表明,在高风险的骨质疏松症患者中,骨类合成药对口服双酸盐的优势.
研究的目的:
- 定义高危骨质疏松症患者,并制定最佳治疗策略.
- 为指导骨质疏松症管理的第一线治疗选择和随后的治疗升级.
主要方法:
- 随机比较性研究的综述,比较骨类合成药和抗吸收药.
- 分析定义高风险骨质疏松症的标准,包括临床表现,T分数和风险计算器.
主要成果:
- 在高风险的骨质疏松症患者中,骨类合成药对口服双酸盐具有优越性.
- 高风险患者是通过关节/脊椎骨折,非常低的T分数或超过风险计算器值来识别的.
- 高风险患者的第一线治疗应该是骨类合成药物,如果需要的话,可以从抗吸收药升级.
结论:
- 建议使用骨类合成药物作为高风险骨质疏松症患者的第一线治疗.
- 抗吸收疗法是必要的随访治疗后,骨类合成药剂.
- 药物假期通常不建议高风险的骨质疏松症患者.
更多相关视频
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
相关概念视频
Bone Remodeling
Venous Thrombosis III: Interprofessional Care
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Fractures: Bone Repair
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
